Pharmaceutical Executive January 11, 2022
Barbara Ryan

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

A decade ago, my colleagues at EY (where I am a senior advisor) created the Firepower Index to understand a company’s total capacity to fund deals to achieve their growth goals. EY defines Firepower by the strength of a company’s balance sheet and market capitalization.

In 2021, the biopharma industry’s M&A Firepower reached a whopping $1.2 trillion, a level not seen since 2014, and 14% ahead of 2020. M&A, alliances, and partnerships have always been core to driving the industry’s growth strategies and satisfy their need to access innovation and talent, and this will remain the case.

However, the nature of dealmaking does shift with the times. The looming loss...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Survey / Study, Trends
A closer look at 2023's top biopharma deals and what lies ahead
Project Optimus: helping or hindering cancer drug development?
Faster Drug Discovery: Yseop & AWS Unveils GenAI Tool for Biopharma R&D
Quest to ramp up AI capabilities with purchase of PathAI’s diagnostic lab
Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test

Share This Article